1. Academic Validation
  2. Targeted Protein O-GlcNAcylation Using Bifunctional Small Molecules

Targeted Protein O-GlcNAcylation Using Bifunctional Small Molecules

  • J Am Chem Soc. 2024 Apr 10;146(14):9779-9789. doi: 10.1021/jacs.3c14380.
Bowen Ma 1 Khadija Shahed Khan 1 2 Tongyang Xu 1 Josefina Xeque Amada 1 Zhihao Guo 1 Yunpeng Huang 1 Yu Yan 1 Henry Lam 3 Alfred Sze-Lok Cheng 2 Billy Wai-Lung Ng 1 4
Affiliations

Affiliations

  • 1 School of Pharmacy, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
  • 2 School of Biomedical Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
  • 3 Department of Chemical and Biological Engineering, The Hong Kong University of Science and Technology, Sai Kung, Hong Kong.
  • 4 Li Ka Shing Institute of Health Sciences, Faculty of Medicine, The Chinese University of Hong Kong, Sha Tin, Hong Kong.
Abstract

Protein O-linked β-N-acetylglucosamine modification (O-GlcNAcylation) plays a crucial role in regulating essential cellular processes. The disruption of the homeostasis of O-GlcNAcylation has been linked to various human diseases, including Cancer, diabetes, and neurodegeneration. However, there are limited chemical tools for protein- and site-specific O-GlcNAc modification, rendering the precise study of the O-GlcNAcylation challenging. To address this, we have developed heterobifunctional small molecules, named O-GlcNAcylation TArgeting Chimeras (OGTACs), which enable protein-specific O-GlcNAcylation in living cells. OGTACs promote O-GlcNAcylation of proteins such as BRD4, CK2α, and EZH2 in cellulo by recruiting FKBP12F36V-fused O-GlcNAc transferase (OGT), with temporal, magnitude, and reversible control. Overall, the OGTACs represent a promising approach for inducing protein-specific O-GlcNAcylation, thus enabling functional dissection and offering new directions for O-GlcNAc-targeting therapeutic development.

Figures
Products
Inhibitors & Agonists